

ACT-AD

Accelerate Cure/Treatments for Alzheimer's Disease

11th Annual FDA/Alzheimer's Disease Allies Meeting
The Promise and Challenges of Big Data Approaches for Biomarker Discovery, Drug Repositioning and Combination Therapy Development for Alzheimer's

Hyatt Regency Bethesda
One Bethesda Metro Center (7400 Wisconsin Ave.), Bethesda, MD 20814
December 5, 2018
REGENCY III/IV | 9:00 am – 4:00 pm

OBJECTIVES

The Accelerate Cure/Treatments for Alzheimer's Disease (ACT-AD) Coalition's 11th annual FDA/Allies meeting will explore the state of big data approaches in Alzheimer's disease and the opportunities it presents as part of this dramatic shift in the way we approach disease. The meeting will also provide a forum for receiving updates on the National Institutes of Health's investment in research to advance our understanding of large data sets to personalize treatments that target a patient's unique genetic makeup. A series of expert presentations will be followed by robust discussions with the leaders from the National Institute on Aging, Centers for Medicare & Medicaid Services, and the FDA's Division of Neurology Products. These discussions will help to assist the field in more rapidly deploying knowledge on the use of big data technology to identify patterns to slow or stop the progress of Alzheimer's disease.

WELCOME

9:00-9:30 a.m. **Registration and Breakfast**

9:30-10:00 a.m. **Welcome and Introductions**

PRESENTATIONS

10:00-10:40 a.m. **Building an Open Science Ecosystem to Enable Predictive Drug Development for AD**

Suzana Petanceska, Ph.D., National Institute on Aging
Laurie Ryan, Ph.D., National Institute on Aging

10:40-11:00 a.m. **Discussion**

11:00-11:20 a.m. **Integrative Proteomics for Biomarker Discovery in AD – Are we There Yet?**

Nick Seyfried, Ph.D., Emory University School of Medicine

11:20-11:40 a.m. **Discussion**

11:40-12:00 p.m. **Digital Biomarkers in the Era of Precision Medicine**

Larsson Omberg, Ph.D. Sage Bionetworks

12:00-12:20 p.m. **Discussion**

- 12:20-12:50 p.m. **Lunch**
- 12:50-1:10 p.m. **Quantifying Brain Wellness and Disease with Digital Biomarkers**
Rhoda Au, Ph.D., Boston University
- 1:10-1:30 p.m. **Discussion**
- 1:30-1:50 p.m. **Industry Perspective on Digital Biomarkers for AD/ADRD**
Jim Harris, Roche Diagnostics
Denise Heaney, Ph.D., Roche Diagnostics
- 1:50-2:10 p.m. **Discussion**
- 2:10-2:30 p.m. **Leveraging Diverse Types of Big Data to Advance Rational Drug Repurposing in AD**
Mark Albers, M.D., Ph.D., Harvard University
- 2:30-2:50 p.m. **Discussion**
- 2:50-3:00 p.m. **Clinical Analytics Platform for Linking Outcomes to Trends Complex Data**
Nikhil Gopinath, M.S., Saama Technologies
- 3:00-3:20 p.m. **Developing a AI Technologies to Enable Data-Driven Drug Development**
Rong Xu, Ph.D., Case Western Reserve University
- 3:20-3:50 p.m. **Discussion**

CLOSING

- 3:50-4:00 p.m. **Summary and Concluding Remarks**